Atossa Therapeutics And Quantum Leap Healthcare Collaborative Dose First Patient In Clinical Trial Evaluating (Z)-Endoxifen With Abemaciclib As Neoadjuvant Treatment For High-Risk ER+/HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics, in collaboration with Quantum Leap Healthcare Collaborative, has dosed the first patient in a clinical trial evaluating (Z)-Endoxifen with Abemaciclib as a neoadjuvant treatment for high-risk ER+/HER2- breast cancer.
August 21, 2024 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics has initiated a clinical trial with Quantum Leap Healthcare Collaborative, dosing the first patient with (Z)-Endoxifen and Abemaciclib for high-risk ER+/HER2- breast cancer.
The initiation of a clinical trial and dosing of the first patient is a significant milestone for Atossa Therapeutics, potentially leading to positive developments in their product pipeline. This could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90